Plavix
AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.
If you or a loved one are in need of legal assistance concerning Plavix you should get a lawyer on your side immediately. You will pay no attorney fees unless you win your case.
Email up to 10 Plavix law firms in one click; by filling out the simple Free Case Evaluation form.
For additional info on Plavix use the related topic links on the far right.
Plavix In The News
Schering's Peacock ImitationThe company lays out its pipeline for investors to digest.
Schering-Plough touts pipeline over competitors'Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday.
Sanofi-Aventis Upped To Overweight By Morgan StanleySanofi-Aventis Upped To Overweight By Morgan Stanley
Schering’s Hassan Looks Past Vytorin, Touts Research (Update2)Nov. 24 (Bloomberg) -- Schering-Plough Corp. plans to begin selling products in the next four years that may generate more than $7 billion in combined annual revenue, lessening the company’s dependence on embattled cholesterol pills.
Intellectual PropertyOn November 6, 2008, the Supreme Court released its decision in Apotex Inc. v. Sanofi-Synthelabo Canada Inc. The primary issue before the court was the validity of selection patents.
Sanofi Raised to `Overweight' at Morgan Stanley on Cost CutsNov. 24 (Bloomberg) -- Sanofi-Aventis SA , France's largest drugmaker, was raised to ``overweight' from ``equal weight' at Morgan Stanley, which said its new chief executive, Chris Viehbacher , was likely to cut research expenses.
Schering-Plough touts pipeline over competitors'Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday. The drugmaker has three drugs awaiting U.S. approval and nine more in final human testing - including a new type of anticlotting drug that could grab some of blockbuster ..
Sanofi Gains After Morgan Stanley Raises Rating, Price EstimateNov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in five weeks in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”
Analyst expects aggressive M&A in big pharmaLarge mergers and buyouts may be on the way in the pharmaceutical sector, a Deutsche Bank analyst said, because drug makers can't keep up their current level of spending in the face of expiring patents and conservative regulators.
Sanofi Gains Most Since 1989 on Morgan Stanley Rating (Update1)Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in 19 years in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”
